Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases

Chongshan Liao; Chengfei Zhang; Yanqi Yang

doi:10.2174/1381612823666170519120040

Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases

Curr Pharm Des. 2017;23(41):6302-6309. doi: 10.2174/1381612823666170519120040.

Authors

Chongshan Liao¹, Chengfei Zhang², Yanqi Yang¹

Affiliations

¹ Orthodontics, Faculty of Dentistry, The University of Hong Kong, Sai Ying Pun, Hong Kong SAR, China.
² Endodontology, Faculty of Dentistry, The University of Hong Kong, Sai Ying Pun, Hong Kong SAR, China.

PMID: 28741455
DOI: 10.2174/1381612823666170519120040

Abstract

Bone remodelling is a strictly regulated dynamic process between bone resorption and bone formation. Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis (SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes the current knowledge of IL-17 signalling pathways. Typical IL-17-mediated bone destruction disorders are examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory loss of bone targeting IL-17.

Keywords: IL-17; IL-17 receptor; RANKL; bone loss; osteoclastogensis; osteoclasts..

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Bone Diseases / drug therapy
Bone Diseases / metabolism*
Bone Resorption / drug therapy
Bone Resorption / metabolism*
Humans
Inflammation / drug therapy
Inflammation / metabolism
Interleukin-17 / antagonists & inhibitors
Interleukin-17 / metabolism*
Signal Transduction / drug effects

Substances

Interleukin-17